WO2020061249A3 - Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation - Google Patents

Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2020061249A3
WO2020061249A3 PCT/US2019/051825 US2019051825W WO2020061249A3 WO 2020061249 A3 WO2020061249 A3 WO 2020061249A3 US 2019051825 W US2019051825 W US 2019051825W WO 2020061249 A3 WO2020061249 A3 WO 2020061249A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
contact lens
artificial tear
methods
drug vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/051825
Other languages
English (en)
Other versions
WO2020061249A2 (fr
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ps Therapies Ltd
Original Assignee
Ps Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/137,738 external-priority patent/US20190021990A1/en
Priority claimed from US16/372,625 external-priority patent/US11583496B2/en
Priority claimed from US16/372,582 external-priority patent/US20190224136A1/en
Priority claimed from US16/372,596 external-priority patent/US20190225917A1/en
Priority claimed from US16/412,943 external-priority patent/US20190262290A1/en
Priority to BR112021005097-3A priority Critical patent/BR112021005097A2/pt
Priority to JP2021515543A priority patent/JP2022511335A/ja
Priority to EP19863887.6A priority patent/EP3853317A4/fr
Application filed by Ps Therapies Ltd filed Critical Ps Therapies Ltd
Priority to CN201980077116.6A priority patent/CN113227304A/zh
Priority to CA3112278A priority patent/CA3112278A1/fr
Publication of WO2020061249A2 publication Critical patent/WO2020061249A2/fr
Publication of WO2020061249A3 publication Critical patent/WO2020061249A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions de larmes artificielles, des compositions de larmes artificielles sous forme de gel, des compositions de stockage de lentilles de contact, des compositions de traitement de lentilles de contact, des compositions de véhicule pour médicament ophtalmologique et des compositions de véhicule pour médicament topique comprenant un ou plusieurs tensioactifs non ioniques avec un ou plusieurs excipients d'amélioration de la viscosité non newtonienne et un ou plusieurs éléments parmi un polyol et/ou un électrolyte et leurs procédés d'utilisation.
PCT/US2019/051825 2018-09-21 2019-09-19 Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation Ceased WO2020061249A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3112278A CA3112278A1 (fr) 2018-09-21 2019-09-19 Larmes artificielles, lentilles de contact et compositions de vehicule pour medicament et leurs procedes d'utilisation
CN201980077116.6A CN113227304A (zh) 2018-09-21 2019-09-19 人工泪液、隐形眼镜和药物载体组合物及其使用方法
BR112021005097-3A BR112021005097A2 (pt) 2018-09-21 2019-09-19 lágrima artificial, lentes de contato e composições de veículos medicinais e métodos de uso dos mesmos
EP19863887.6A EP3853317A4 (fr) 2018-09-21 2019-09-19 Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation
JP2021515543A JP2022511335A (ja) 2018-09-21 2019-09-19 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US16/137,738 2018-09-21
US16/137,738 US20190021990A1 (en) 2016-10-12 2018-09-21 Artificial tear compositions and methods of use thereof
US16/372,582 2019-04-02
US16/372,596 2019-04-02
US16/372,596 US20190225917A1 (en) 2016-10-12 2019-04-02 Contact lens compositions and methods of use thereof
US16/372,582 US20190224136A1 (en) 2016-10-12 2019-04-02 Artificial tear compositions and methods of use thereof
US16/372,625 US11583496B2 (en) 2016-10-12 2019-04-02 Drug vehicle compositions and methods of use thereof
US16/372,625 2019-04-02
US16/412,943 2019-05-15
US16/412,943 US20190262290A1 (en) 2016-10-12 2019-05-15 Drug vehicle compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2020061249A2 WO2020061249A2 (fr) 2020-03-26
WO2020061249A3 true WO2020061249A3 (fr) 2020-07-23

Family

ID=69887791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/051825 Ceased WO2020061249A2 (fr) 2018-09-21 2019-09-19 Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP3853317A4 (fr)
JP (1) JP2022511335A (fr)
CN (1) CN113227304A (fr)
BR (1) BR112021005097A2 (fr)
CA (1) CA3112278A1 (fr)
WO (1) WO2020061249A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2022189552A1 (fr) * 2021-03-10 2022-09-15 Bausch + Lomb Ireland Limited Solution de traitement de lentilles de contact sans conservateur
US12397518B2 (en) * 2021-04-29 2025-08-26 Coopervision International Limited WS12-releasing contact lens
CN115671256B (zh) * 2021-07-30 2024-04-09 四川大学华西医院 环孢素a与地夸磷索钠联合使用在制备治疗干眼症的药物中的用途
JP7664495B2 (ja) * 2022-10-31 2025-04-17 クーパーヴィジョン インターナショナル リミテッド Ｗｓ１２－放出コンタクトレンズ
CN117338787A (zh) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 一种眼用药物组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
US8597629B1 (en) * 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US20160213609A1 (en) * 2015-01-26 2016-07-28 Bausch & Lomb Incorporated Ophthalmic suspension composition
US20180098937A1 (en) * 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239518A1 (en) * 2007-09-14 2010-09-23 Yasuko Matsumura Ophthalmic composition
AU2010339993A1 (en) * 2009-12-15 2012-07-26 Foresight Biotherapeutics, Inc. Non-irritating ophthalmic povidone-iodine compositions
JP7324566B2 (ja) * 2015-05-28 2023-08-10 ロート製薬株式会社 水性眼科組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097592A1 (en) * 2000-09-13 2004-05-20 Kenji Morishima Eye drops
US8597629B1 (en) * 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US20160213609A1 (en) * 2015-01-26 2016-07-28 Bausch & Lomb Incorporated Ophthalmic suspension composition
US20180098937A1 (en) * 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Also Published As

Publication number Publication date
CA3112278A1 (fr) 2020-03-26
EP3853317A2 (fr) 2021-07-28
JP2022511335A (ja) 2022-01-31
CN113227304A (zh) 2021-08-06
EP3853317A4 (fr) 2022-06-22
WO2020061249A2 (fr) 2020-03-26
BR112021005097A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
WO2020061249A3 (fr) Larmes artificielles, lentilles de contact et compositions de véhicule pour médicament et leurs procédés d'utilisation
EP4445954A3 (fr) Modèles cellulaires et thérapies pour maladies oculaires
CA3285799A1 (en) Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
IL287128B1 (en) GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases
EP4706671A3 (fr) Mimétiques d'hepcidine conjugués
WO2019099868A3 (fr) Agents de dégradation et dégrons pour dégradation protéique ciblée
CL2020001783A1 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
EP4596041A3 (fr) Agonistes du récepteur farnésoïde x et leursutilisations
WO2006039467A3 (fr) Dispositifs biomedicaux contenant des copolymeres sequences amphiphiles
MX2024000349A (es) Compuestos y usos de los mismos.
EP4003225A4 (fr) Formulations d'encre biologique, lenticule cornéen bio-imprimé et applications associées
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
WO2019209962A8 (fr) Composés et leurs utilisations
WO2019209948A8 (fr) Composés et leurs utilisations
EP3606570B8 (fr) Compositions médicamenteuses à base de collagène peptidique pour l'utilisation dans le traitement des maladies, troubles ou blessures oculaires
WO2018017190A3 (fr) Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
WO2019175260A3 (fr) Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
EP3758693A4 (fr) Utilisation de l'acide (1s,3s)-3-amino-4-(difluorométhylidène) cyclopentane-1-carboxylique et de l'acide (s)-3-amino-4-(difluorométhylényl)cyclopent-1-ène-1-carboxylique dans le traitement de troubles oculaires
EP3737431A4 (fr) Méthodes, formulations contenant un polymère et compositions polymères pour traiter un décollement de rétine et d'autres troubles oculaires
WO2020097021A3 (fr) Agent de protection dermique et excipient
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
CL2020001339A1 (es) Composiciones y métodos de uso para tratar la inflamación aberrante en las glándulas secretoras peri-oculares o en la superficie ocular.
HK1256814A1 (zh) 用於在药物中使用的胶体颗粒
WO2018211323A8 (fr) Composés hétérocycliques pour traiter une maladie
WO2017129577A8 (fr) Gabapentine ophtalmique pour le traitement d'ulcères cornéens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19863887

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3112278

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021515543

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021005097

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019863887

Country of ref document: EP

Effective date: 20210421

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19863887

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112021005097

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210317

WWW Wipo information: withdrawn in national office

Ref document number: 2019863887

Country of ref document: EP